Working… Menu

Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03009682
Recruitment Status : Completed
First Posted : January 4, 2017
Last Update Posted : February 18, 2021
Information provided by (Responsible Party):
Keunchil Park, Samsung Medical Center

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 2021
Actual Study Completion Date : January 2021